Puma Biotechnology delivered a robust performance in Q2 2025, with total revenue reaching $52.4 million, up from $47.1 million in Q2 2024. The company achieved a net income of $5.9 million, a substantial turnaround from a net loss of $4.5 million in the same period last year. This positive shift was primarily fueled by increased product revenue from NERLYNX® and reduced selling, general, and administrative expenses.
Total revenue for Q2 2025 increased to $52.4 million, up from $47.1 million in Q2 2024, primarily due to higher product and royalty revenue.
The company reported a net income of $5.9 million ($0.12 per share) in Q2 2025, a significant improvement from a net loss of $4.5 million ($0.09 per share) in Q2 2024.
Non-GAAP adjusted net income for Q2 2025 was $7.5 million ($0.15 per share), compared to a non-GAAP adjusted net loss of $2.5 million ($0.05 per share) in Q2 2024.
Net cash provided by operating activities saw a substantial increase to $14.1 million in Q2 2025, up from $1.0 million in Q2 2024.
Puma Biotechnology provided a positive financial outlook for Q3 and Full Year 2025, anticipating continued revenue growth and net income.
Analyze how earnings announcements historically affect stock price performance